Charles Schwab Investment Management Inc Rapt Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 70,979 shares of RAPT stock, worth $86,594. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,979

Previous 70,946 0.05%

Holding current value

$86,594

Previous $142,000 21.13%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$0.81 - $3.1 $26 - $102	33 Added 0.05%	70,979 $112,000
Q3 2024 Nov 12, 2024	SELL	$1.76 - $3.75 $241,457 - $514,470	-137,192 Reduced 65.91%	70,946 $142,000
Q2 2024 Aug 12, 2024	SELL	$2.89 - $9.38 $79,527 - $258,118	-27,518 Reduced 11.68%	208,138 $634,000
Q1 2024 May 08, 2024	BUY	$6.87 - $26.45 $8,360 - $32,189	1,217 Added 0.52%	235,656 $2.12 Million
Q4 2023 Feb 06, 2024	BUY	$11.28 - $25.46 $142,692 - $322,069	12,650 Added 5.7%	234,439 $5.83 Million
Q3 2023 Nov 08, 2023	BUY	$16.34 - $24.66 $391,244 - $590,459	23,944 Added 12.1%	221,789 $3.69 Million
Q2 2023 Aug 09, 2023	BUY	$16.06 - $21.61 $46,236 - $62,215	2,879 Added 1.48%	197,845 $3.7 Million
Q1 2023 May 11, 2023	BUY	$17.19 - $30.8 $408,761 - $732,393	23,779 Added 13.89%	194,966 $3.58 Million
Q4 2022 Feb 13, 2023	BUY	$16.28 - $24.6 $76,516 - $115,620	4,700 Added 2.82%	171,187 $3.39 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $252,679 - $428,541	14,069 Added 9.23%	166,487 $4.01 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $23.59 $67,716 - $155,694	6,600 Added 4.53%	152,418 $2.78 Million
Q1 2022 May 13, 2022	BUY	$17.02 - $40.22 $63,739 - $150,623	3,745 Added 2.64%	145,818 $3.21 Million
Q4 2021 Feb 11, 2022	BUY	$29.5 - $39.5 $57,200 - $76,590	1,939 Added 1.38%	142,073 $5.22 Million
Q3 2021 Nov 16, 2021	BUY	$29.86 - $39.47 $1.77 Million - $2.34 Million	59,374 Added 73.52%	140,134 $4.35 Million
Q2 2021 Aug 16, 2021	BUY	$17.99 - $40.02 $265,478 - $590,575	14,757 Added 22.36%	80,760 $2.57 Million
Q1 2021 May 17, 2021	SELL	$16.0 - $24.46 $5,472 - $8,365	-342 Reduced 0.52%	66,003 $1.47 Million
Q4 2020 Feb 16, 2021	BUY	$15.89 - $40.87 $15,063 - $38,744	948 Added 1.45%	66,345 $1.31 Million
Q3 2020 Nov 13, 2020	BUY	$21.6 - $37.5 $294,645 - $511,537	13,641 Added 26.36%	65,397 $2.11 Million
Q2 2020 Aug 14, 2020	BUY	$14.16 - $32.85 $313,275 - $726,773	22,124 Added 74.66%	51,756 $1.5 Million
Q1 2020 May 15, 2020	BUY	$11.86 - $48.86 $159,339 - $656,434	13,435 Added 82.95%	29,632 $631,000
Q4 2019 Feb 07, 2020	BUY	$12.3 - $30.78 $199,223 - $498,543	16,197 New	16,197 $448,000

Others Institutions Holding RAPT

# of Institutions

100

Shares Held

124M

Call Options Held

246K

Put Options Held

69.6K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $36.2M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Rapt Therapeutics, Inc. Transaction History